Citrobacter braakii urinary tract infection in chronic kidney disease

Vathsala Mohan; Clay Golledge; Jonathan Grasko; Yael Grasko

doi:10.1071/MA24031

RESEARCH ARTICLE (Open Access)

Previous Next Contents Vol 45(3)

Citrobacter braakii urinary tract infection in chronic kidney disease

Vathsala Mohan ^A ^* , Clay Golledge ^A , Jonathan Grasko ^B and Yael Grasko ^B

+ Author Affiliations

- Author Affiliations

^A Department of Microbiology, Saturn Pathology, 31, Cedric Street, Stirling, WA, Australia.

^B Department of Biochemistry, Saturn Pathology, 31, Cedric Street, Stirling WA, Australia.

Dr Ala (Vathsala) Mohan has a PhD in molecular epidemiology from Massey University, New Zealand, and has vast experience in biomedical sectors like recombinant DNA technology, immuno‐diagnostics and reproductive biotechnology. Ala’s expertise includes human gut health and nutrition, human pathogens and food safety. Previous roles include Operations and Technical Manager (Livestock Improvement Corporation, New Zealand), SARS‐CoV2 diagnostic medical lab scientist (Auckland Health District Board, New Zealand), and senior medical laboratory scientist and Quality Assurance Manager for National Association of Testing Authorities (NATA), WA, Australia. Currently Ala is contributing to CSIRO’s antimicrobial resistance research.

Clay Golledge is the Executive Director at Infections West, Hollywood Medical Centre. Clay has worked as a Senior Consultant in microbiology at the Health Department Western Australia and PathWest Sir Charles Gairdner Hospital (SCGH).

Jonathan Grasko is a chemical pathologist and the Managing Director of Saturn Pathology. Jonathan has expertise in toxicology and served in different pathology services as a chemical and toxicology expert for more than a decade.

Yael Grasko is a chemical pathologist and has a business management specialisation. Yael is the Medical Director of Saturn Pathology and has worked as a chemical pathologist in QML Pathology Services and other pathology facilities for more than a decade.

^* Correspondence to: lingvathsala@gmail.com

Microbiology Australia 45(3) 151-154 https://doi.org/10.1071/MA24031

Submitted: 30 September 2023 Accepted: 10 February 2024 Published: 20 June 2024

© 2024 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of the ASM. This is an open access article distributed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC)

Abstract

We report urinary tract infection caused by Citrobacter braakii in an 83-old female patient with chronic kidney disease. The isolate was confirmed with bacteria analytical profile index and MALDI-TOF identification methods. A urine sample was presented to the lab for investigating urinary tract infection along with blood biochemistry and whole blood picture investigation. Antimicrobial susceptibility tests were carried out based on the Clinical and Laboratory Standards Institute’s guidelines and the isolate was resistant to ampicillin and amoxycillin clavulanate.

Keywords: amoxicillin clavulanate resistance, amoxicillin resistance, API, chronic kidney disease, Citrobacter braackii, elderly female patient, MALDI-TOF, urinary tract infection.

Biographies

Dr Ala (Vathsala) Mohan has a PhD in molecular epidemiology from Massey University, New Zealand, and has vast experience in biomedical sectors like recombinant DNA technology, immuno‐diagnostics and reproductive biotechnology. Ala’s expertise includes human gut health and nutrition, human pathogens and food safety. Previous roles include Operations and Technical Manager (Livestock Improvement Corporation, New Zealand), SARS‐CoV2 diagnostic medical lab scientist (Auckland Health District Board, New Zealand), and senior medical laboratory scientist and Quality Assurance Manager for National Association of Testing Authorities (NATA), WA, Australia. Currently Ala is contributing to CSIRO’s antimicrobial resistance research.

Clay Golledge is the Executive Director at Infections West, Hollywood Medical Centre. Clay has worked as a Senior Consultant in microbiology at the Health Department Western Australia and PathWest Sir Charles Gairdner Hospital (SCGH).

Jonathan Grasko is a chemical pathologist and the Managing Director of Saturn Pathology. Jonathan has expertise in toxicology and served in different pathology services as a chemical and toxicology expert for more than a decade.

Yael Grasko is a chemical pathologist and has a business management specialisation. Yael is the Medical Director of Saturn Pathology and has worked as a chemical pathologist in QML Pathology Services and other pathology facilities for more than a decade.

References

1 Foxman B (2010) The epidemiology of urinary tract infection. Nat Rev Urol 7, 653-660.
| Crossref | Google Scholar | PubMed |

2 Zalmanovici Trestioreanu A et al. (2010) Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 10, CD007182.
| Crossref | Google Scholar |

3 Mitchell B et al. (2014) Healthcare associated urinary tract infections: a protocol for a national point prevalence study. Healthc Infect 19, 26-31.
| Crossref | Google Scholar |

4 Gardner A et al. (2014) A point prevalence cross-sectional study of healthcare-associated urinary tract infections in six Australian hospitals. BMJ Open 4, e005099.
| Crossref | Google Scholar | PubMed |

5 Pitart C et al. (2015) Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 59, 3059-3065.
| Crossref | Google Scholar | PubMed |

6 Vohra P et al. (2015) Bacterial uropathogens in urinary tract infection and their antibiotic susceptibility pattern in a tertiary care hospital. Int J Curr Microbiol Appl Sci 4, 696-699.
| Google Scholar |

7 Arens S et al. (1997) Differentiation and susceptibility of Citrobacter isolates from patients in a university hospital. Clin Microbiol Infect 3, 53-57.
| Crossref | Google Scholar | PubMed |

8 Sakazaki R (1984) Genus IV. In Citrobacter, in Bergey’s manual of systematic bacteriology (Krieg NR, Holt JG, eds). pp. 458–461. The Williams & Wilkins Co., Baltimore, MD, USA.

9 Brenner DJ et al. (1993) Classification of citrobacteria by DNA hybridization: designation of Citrobacter farmeri sp. nov., Citrobacter youngae sp. nov., Citrobacter braakii sp. nov., Citrobacter werkmanii sp. nov., Citrobacter sedlakii sp. nov., and three unnamed Citrobacter genomospecies. Int J Syst Bacteriol 43, 645-658.
| Crossref | Google Scholar | PubMed |

10 Rashedmarandi F et al. (2008) A survey on urinary pathogens and their antimicrobial susceptibility among patients with significant bacteriuria. Iran J Pathol 3, 191-196.
| Google Scholar |

11 Barton LL, Walentik C (1982) Citrobacter diversus urinary tract infection. Am J Dis Child 136, 467-468.
| Crossref | Google Scholar | PubMed |

12 Whitby J, Muir G (1961) Bacteriological studies of urinary tract infection. Br J Urol 33, 130-134.
| Crossref | Google Scholar | PubMed |

13 Valencia R et al. (2009) Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 30, 257-63.
| Crossref | Google Scholar | PubMed |

14 Sami H et al. (2017) Citrobacter as a uropathogen, its prevalence and antibiotics susceptibility pattern. CHRISMED J Health Res 4, 23-26.
| Crossref | Google Scholar |

15 Barton LL, Walentik C (1982) Citrobacter diversus urinary tract infection. Am J Dis Child 136, 467-468.
| Crossref | Google Scholar | PubMed |

16 Lipsky BA et al. (1980) Citrobacter infections in humans: experience at the Seattle Veterans Administration Medical Center and a review of the literature. Rev Infect Dis 2, 746-760.
| Crossref | Google Scholar | PubMed |

17 Brenner DJ et al. (1999) Biochemical identification of Citrobacter species defined by DNA hybridization and description of Citrobacter gillenii sp. nov. (formerly Citrobacter genomospecies 10) and Citrobacter murliniae sp. nov. (formerly Citrobacter genomospecies 11). J Clin Microbiol 37, 2619-2624.
| Crossref | Google Scholar | PubMed |

18 Clinical and Laboratory Standards Institute (2022) M100 – Performance Standards For Antimicrobial Susceptibility Testing. CLSI. https://clsi.org/standards/products/microbiology/documents/m100/

19 Mortier T et al. (2021) Bacterial species identification using MALDI-TOF mass spectrometry and machine learning techniques: a large-scale benchmarking study. Comput Struct Biotechnol J 19, 6157-6168.
| Crossref | Google Scholar | PubMed |

20 Hirai J et al. (2016) Bacteremia due to Citrobacter braakii: a case report and literature review. J Infect Chemother 22, 819-821.
| Crossref | Google Scholar | PubMed |

21 Moland ES et al. (2006) Prevalence of newer β-lactamases in Gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 44, 3318-3324.
| Crossref | Google Scholar | PubMed |

22 Park Y-J et al. (2005) Occurrence of extended-spectrum β-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Microbiol Infect Dis 51, 265-269.
| Crossref | Google Scholar | PubMed |

23 Kanamori H et al. (2011) High prevalence of extended-spectrum β-lactamases and qnr determinants in Citrobacter species from Japan: dissemination of CTX-M-2. J Antimicrob Chemother 66, 2255-2262.
| Crossref | Google Scholar | PubMed |

24 Liu L et al. (2017) Antimicrobial resistance and cytotoxicity of Citrobacter spp. in Maanshan Anhui Province, China. Front Microbiol 8, 1357.
| Crossref | Google Scholar | PubMed |

25 Park Y-J et al. (2007) Prevalence and diversity of qnr alleles in AmpC-producing Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Serratia marcescens: a multicentre study from Korea. J Antimicrob Chemother 60, 868-871.
| Crossref | Google Scholar | PubMed |